Dissolve-E: AWMF Guideline Registry
0.2.0 - ci-build

Dissolve-E: AWMF Guideline Registry - Local Development build (v0.2.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

: Situationen mit Empfehlungen gegen eine Knochenmarkbiopsie - JSON Representation

Raw json | Download

{
  "resourceType" : "Composition",
  "id" : "RecommendationAgainstBoneMarrowBiopsy",
  "meta" : {
    "profile" : [
      🔗 "http://fhir.awmf.org/awmf.ig/StructureDefinition/recommendation"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" dir=\"ltr\">Situationen mit Empfehlungen gegen eine Knochenmarkbiopsie</div>"
  },
  "identifier" : [
    {
      "use" : "official",
      "system" : "http://fhir.awmf.org/examples",
      "value" : "RecommendationAgainstBoneMarrowBiopsy"
    }
  ],
  "version" : "2022",
  "status" : "final",
  "type" : {
    "coding" : [
      {
        "system" : "https://fevir.net/resources/CodeSystem/179423",
        "code" : "Recommendation",
        "display" : "Recommendation"
      }
    ]
  },
  "category" : [
    {
      "coding" : [
        {
          "system" : "http://fhir.awmf.org/awmf.ig/CodeSystem/cs-recommendation-synthesis-type",
          "code" : "evidence-based",
          "display" : "Evidence-based"
        }
      ]
    }
  ],
  "date" : "2022-10-01",
  "author" : [
    {
      🔗 "reference" : "Organization/DGHO"
    },
    {
      🔗 "reference" : "PractitionerRole/UlrichDuehrsenDGIMFor018-038"
    },
    {
      🔗 "reference" : "PractitionerRole/DirkHellwigDGNFor018-038"
    },
    {
      🔗 "reference" : "PractitionerRole/ThorstenPersigehlDRGFor018-038"
    },
    {
      🔗 "reference" : "PractitionerRole/LaleUmutluDRGFor018-038"
    }
  ],
  "title" : "Situationen mit Empfehlungen gegen eine Knochenmarkbiopsie",
  "relatesTo" : [
    {
      "type" : "part-of",
      "targetCanonical" : "http://fhir.awmf.org/awmf.ig/Composition/DiffuseLargeBCellLymphomaGuideline|2022"
    }
  ],
  "section" : [
    {
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "recommendation-statement",
            "display" : "Recommendation Statement"
          }
        ]
      },
      "section" : [
        {
          "extension" : [
            {
              "url" : "http://fhir.awmf.org/awmf.ig/StructureDefinition/ext-section-language",
              "valueCode" : "de"
            }
          ],
          "code" : {
            "coding" : [
              {
                "system" : "http://fhir.awmf.org/awmf.ig/CodeSystem/cs-guideline-sections",
                "code" : "language",
                "display" : "Language"
              }
            ]
          },
          "text" : {
            "status" : "generated",
            "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" dir=\"ltr\"><div><p>Bei Einsatz der PET/CT zur Stadieneinteilung soll bei kurativem Konzept in folgenden Situationen auf eine Knochenmarkbiopsie verzichtet werden:</p><ul><li>Nachweis einer Knochenmarkbeteiligung durch die PET/CT</li><li>Fortgeschrittenes Ausbreitungsstadium (Ann Arbor-Stadium III oder IV; <a>s. 5.2.3.1</a>)</li><li>Limitiertes Ausbreitungsstadium (Ann Arbor-Stadium I oder II) mit ‚bulky disease‘ (<a>s. 5.3.2.1.</a>) und/oder ≥\u00a01 ungünstigem Faktor des altersadjustierten ‚Internationalen Prognostischen Index‘ (IPI) (s. <a>5.3.1.2</a>).</li></ul></div></div>"
          }
        }
      ]
    }
  ]
}